MARK2 and breast cancer: Similarly, Krishnan et al. demonstrated that inhibition of Ezrin through expression of a non-phosphorylatable mutant results in reduction of phosphorylation of the serine/threonine kinase AKT at serine 473.40 Since then, we hypothesised that the influence of Ezrin in BC at least in part via the AKT pathway.